AQP2 and urogenital neoplasm: So far, we have shown that the release of AQP1‐ and AQP2‐bearing uEVs (uEV‐AQP1 and ‐AQP2) are altered in experimental kidney injury models such as gentamicin (Abdeen et al., 2014), cisplatin (Sonoda et al., 2019), puromycin aminonucleoside (Abdeen et al., 2020), and ischemia/reperfusion (I/R) models (Asvapromtada et al., 2018).